ERBB2 and breast carcinoma: In conclusion, although the sample size of the present pilot study was small and despite the lack of validation cohort, using a high-throughput analysis, we identified genes that were differentially methylated in breast cancer tissues of HER2-positive trastuzumab-treated breast cancer patients who developed resistance toward this drug compared to those who responded to targeted therapy.